Beta Agonist Nebulization in Non Invasively Ventilated COPD Patients: Safety, and Therapeutic Efficacy Range.

Randomization will focus on the treatment administered (placebo or salbutamol ).

After the first phase , a switch will be set up for each patient , retaining the blind it will be administered salbutamol (for those who received placebo in the first phase ) or placebo (for those receiving salbutamol ) .

Inclusion criteria

• Patient over 18 years old
• Patient with BPCO, defined:

• by an irreversible obstructive syndrome
• and\\or by different arguments (histories, symptoms, physical examination, thoracic radiography, gas of the blood)
• Decompensation of this BPCO in the form of acute respiratory failure
• No argument for a dominant acute left cardiac insufficiency
• Consent signed by the patient
• Patient with national health assurance

Exclusion criteria

• Contraindications in the not invasive ventilation
• Patient not volunteer for the realization of the spirometry
• Precautions for use of ß2 mimetic (engrave hyperthyroidism)
• Under guardianship patient or protection of justice
• Pregnant patient